We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Graphene-Based Biosensors Could Detect Sepsis Earlier in Critically Ill Patients

By LabMedica International staff writers
Posted on 09 Jun 2023
Print article
Image: Gii-Sens is the world`s first 3D Graphene foam electrode for biosensing (Photo courtesy of Integrated Graphene)
Image: Gii-Sens is the world`s first 3D Graphene foam electrode for biosensing (Photo courtesy of Integrated Graphene)

Lactate serves as a vital biomarker in managing hospitalized patients who are critically ill. A common complication in intensive care units, hyperlactatemia, can occur either due to insufficient oxygen supply to tissues or underlying conditions such as advanced liver disease. If left untreated, hyperlactatemia can escalate into lactate acidosis, a severe condition that can be life-threatening. Reliable real-time lactate detection, whether via single-point or continuous monitoring, has the potential to enhance patient outcomes in critical care and speed up the diagnosis of sepsis in critically ill individuals. Now, a new study has highlighted the significant potential of graphene-based biosensors for detecting elevated lactate levels.

The study by researchers at the University of Bath (Bath, UK) showed that using Integrated Graphene’s (Stirling, UK) Gii-Sens electrochemical sensor can enhance the diagnostic accuracy of hyperlactatemia. The Gii-Sens, a diagnostic biosensing electrode, outperforms conventional sensing materials by a factor of 10-100, enabling rapid, laboratory-quality testing at the point of need in a cost-effective manner. Gii-Sens electrochemical electrodes, produced using Integrated Graphene’s novel 3D graphene Gii, are disposable sensors designed for one-step assays without the need for pre-treatments.

“Lactate is a naturally occurring biomarker which everyone produces as a byproduct of exercising. For most people it is easily processed by the body and will cause no major harm, apart from a little cramp if you overexert yourself,” said Dr. Marco Caffio, Integrated Graphene’s Co-Founder and CSO. “However, for some critically ill patients and those with underlying conditions it can be a sign of a range of other issues, some of which, like sepsis, can be fatal. Having a robust way of monitoring lactate levels is important in ensuring the best possible outcomes for these patients. The findings of this study demonstrate Gii’s reliable performance and potential to save lives.”

Related Links:
University of Bath 
Integrated Graphene 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.